[go: up one dir, main page]

TWI347194B - Alpha-emitting hydroxyapatite particles - Google Patents

Alpha-emitting hydroxyapatite particles

Info

Publication number
TWI347194B
TWI347194B TW094104922A TW94104922A TWI347194B TW I347194 B TWI347194 B TW I347194B TW 094104922 A TW094104922 A TW 094104922A TW 94104922 A TW94104922 A TW 94104922A TW I347194 B TWI347194 B TW I347194B
Authority
TW
Taiwan
Prior art keywords
alpha
hydroxyapatite particles
emitting
emitting radionuclide
emitting hydroxyapatite
Prior art date
Application number
TW094104922A
Other languages
Chinese (zh)
Other versions
TW200536558A (en
Inventor
Gro Salberg
Roy H Larsen
Original Assignee
Algeta As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta As filed Critical Algeta As
Publication of TW200536558A publication Critical patent/TW200536558A/en
Application granted granted Critical
Publication of TWI347194B publication Critical patent/TWI347194B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)

Abstract

The present invention provides Hydroxyapatite (HA) incorporating an alpha-emitting radionuclide or an in vivo generator for an alpha-emitting radionuclide. The invention further provides methods for the formation of such HA, pharmaceutical compositions comprising the HA and methods of medical treatment of cancerous or non-cancerous disease including administering the HA or compositions thereof.
TW094104922A 2004-02-20 2005-02-18 Alpha-emitting hydroxyapatite particles TWI347194B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0403856.8A GB0403856D0 (en) 2004-02-20 2004-02-20 Composition

Publications (2)

Publication Number Publication Date
TW200536558A TW200536558A (en) 2005-11-16
TWI347194B true TWI347194B (en) 2011-08-21

Family

ID=32040119

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094104922A TWI347194B (en) 2004-02-20 2005-02-18 Alpha-emitting hydroxyapatite particles

Country Status (13)

Country Link
JP (1) JP5214884B2 (en)
KR (2) KR20070038030A (en)
CN (1) CN1972720B (en)
AT (1) ATE544492T1 (en)
DK (1) DK1735013T3 (en)
ES (1) ES2382041T3 (en)
GB (1) GB0403856D0 (en)
IL (1) IL177354A (en)
NO (1) NO20064232L (en)
NZ (1) NZ549080A (en)
PT (1) PT1735013E (en)
TW (1) TWI347194B (en)
ZA (1) ZA200606728B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3111959T1 (en) * 2015-07-03 2018-04-30 Oncoinvent As Radiotherapeutic particles and suspensions
US20170065731A1 (en) * 2015-09-06 2017-03-09 Medical Theranostics Inc. Method, Apparatus, and System for Radiation Therapy
CN106344927A (en) * 2016-09-27 2017-01-25 大连理工大学 Drug-loaded hydroxyapatite modified by folic acid and preparation method thereof
CA3192423A1 (en) * 2020-09-15 2022-03-24 Roy H. Larsen Size controlled radiolabelled particles
WO2024146921A1 (en) * 2023-01-05 2024-07-11 Oncoinvent As Alpha-emitting radionuclides for use in the treatment of peritoneal cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097927A1 (en) * 1990-12-21 1992-06-22 Edward A. Deutsch Radionuclide labelled particles useful for radiation synovectomy
JP4194113B2 (en) * 1993-10-26 2008-12-10 トーマス・ジェファーソン・ユニバーシティ Compositions that specifically bind to colorectal cancer cells and methods of use thereof
WO1997001304A1 (en) * 1995-06-29 1997-01-16 Mallinckrodt Medical, Inc. Radiolabeled apatite particles containing a paramagnetic ion
CN1287859C (en) * 1999-10-18 2006-12-06 费克斯公司 Magnetically guided carriers composed of iron and porous materials for targeted delivery of bioactive agents
JP3836444B2 (en) * 2002-05-30 2006-10-25 独立行政法人科学技術振興機構 Hydroxyapatite composite, method for producing the same, and medical material using the same

Also Published As

Publication number Publication date
ATE544492T1 (en) 2012-02-15
ES2382041T3 (en) 2012-06-04
PT1735013E (en) 2012-05-08
GB0403856D0 (en) 2004-03-24
CN1972720B (en) 2010-07-07
NZ549080A (en) 2011-01-28
KR20100060029A (en) 2010-06-04
KR20070038030A (en) 2007-04-09
JP5214884B2 (en) 2013-06-19
JP2007528373A (en) 2007-10-11
ZA200606728B (en) 2007-12-27
CN1972720A (en) 2007-05-30
IL177354A0 (en) 2006-12-10
DK1735013T3 (en) 2012-05-21
TW200536558A (en) 2005-11-16
KR101165518B1 (en) 2012-07-16
IL177354A (en) 2013-04-30
NO20064232L (en) 2006-09-19

Similar Documents

Publication Publication Date Title
WO2005079867A3 (en) Alpha-emitting hydroxyapatite particles
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
LUC00011I2 (en)
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2003087831A3 (en) Proteins involved in breast cancer
TWI347194B (en) Alpha-emitting hydroxyapatite particles
SE0103210D0 (en) New formulations and use thereof
EA200600987A1 (en) APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORS

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees